Blueprint Medicines Is Maintained at Buy by HC Wainwright & Co.
Blueprint Medicines Is Maintained at Buy by HC Wainwright & Co.
Blueprint Medicines Price Target Raised to $135.00/Share From $125.00 by HC Wainwright & Co.
Blueprint Medicines Price Target Raised to $135.00/Share From $125.00 by HC Wainwright & Co.
HC Wainwright & Co. : The Blueprint Medicines (BPMC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $125.00 to $135.00.
HC Wainwright & Co. : The Blueprint Medicines (BPMC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $125.00 to $135.00.
JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
JMP Securities analyst Reni Benjamin maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and raises the price target from $114 to $125.
Blueprint Medicines Is Maintained at Neutral by Piper Sandler
Blueprint Medicines Is Maintained at Neutral by Piper Sandler
Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)
Sell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth Factors
Ayvakit's Sales Surge Supports Buy Rating and Increased Price Target for Blueprint Medicines
Blueprint Medicines Price Target Raised to $130.00/Share From $97.00 by Needham
Blueprint Medicines Price Target Raised to $130.00/Share From $97.00 by Needham
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $130
Needham analyst Ami Fadia maintains Blueprint Medicines with a Buy and raises the price target from $97 to $130.
Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...
Buy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline Prospects
Earnings Call Summary | Blueprint Medicines(BPMC.US) Q1 2024 Earnings Conference
The following is a summary of the Blueprint Medicines Corporation (BPMC) Q1 2024 Earnings Call Transcript:Financial Performance:Blueprint Medicines reported Q1 2024 EBITDA net product revenue of $92.5
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 1.05 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 2, $Blueprint Medicines(BPMC.US)$ Officer MICHAEL LANDSITTEL intends to sell 10,000 shares of its common stock on May 2, with a total market value of approximately $1.05 mi
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 190.52K in Common Stocks
SEC FILLINGS DISCLOSED/ May 2, $Blueprint Medicines(BPMC.US)$ Officer ARIEL HURLEY intends to sell 1,834 shares of its common stock on May 2, with a total market value of approximately $190.52K. ARI
Blueprint Medicines Shares Hit 52-Week on Strong Ayvakit Sales
By Colin Kellaher Blueprint Medicines shares rose more than 10% and hit a new 52-week high on Thursday after the precision-therapy company posted better-than-expected quarterly sales for its Ayvakit
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating
Blueprint Medicines (BPMC) has an average rating of outperform and price targets ranging from $50 to $130, according to analysts polled by Capital IQ. Price: 106.47, Change: +11.61, Percent Change: +1
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday.Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rose sharply during Thursday's session after the company repo
Blueprint Medicines Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Results and Raised FY24 Revenue Guidance.
Blueprint Medicines Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Results and Raised FY24 Revenue Guidance.
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, Vs. Street Est of $81.4M
07:15 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M
No Data